Aventis Insulin Analog Lantus® Launched in the USA
Lantus is unique in that it has no pronounced peak, and is indicated for once-daily administration at bedtime in the treatment of adult and pediatric patients (6 years of age and older) with type 1 diabetes, or adult patients with type 2 diabetes who require long-acting insulin for the control of hyperglycemia. Lantus was first launched in Germany in June 2000, and has already captured 28 percent of the basal insulin market there.
“This product could change, for the better, the way diabetes is treated,â€
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.